Next-generation sequencing (NGS) enables researchers and drug developers to better understand the biology that drives cancer predisposition and proliferation. These insights have led to the development of targeted therapeutics and multi-analyte tumor analysis. This, in turn, has opened the door for novel methods to monitor cancer treatment and recurrence.
llumina brings innovation to oncology drug development by offering comprehensive genomic solutions and working in collaboration with leading pharmaceutical providers.
As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.Learn More
NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.Learn More